reslizumab
- CAS No.
- 241473-69-8
- Chemical Name:
- reslizumab
- Synonyms
- Sch 55700;reslizumab;Reslizumab (anti-IL-5);Research Grade Reslizumab;Research Grade Reslizumab (DHC13601)
- CBNumber:
- CB34919947
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Reslizumab 99.4% | CS-0030900 | 1mg | $1083 |
| Reslizumab 99.4% | CS-0030900 | 2mg | $1950 |
| Reslizumab 99.4% | CS-0030900 | 1mg | $1083 |
| Reslizumab 99.4% | CS-0030900 | 2mg | $1950 |
| Reslizumab | AA01UNJ9 | 1mg | $550 |
| storage temp. | Store at 4°C,Do not freeze |
|---|---|
| solubility | Soluble in DMSO |
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | 35A26E427H |
| ATC code | R03DX08 |
reslizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0030900 | Reslizumab 99.4% | 241473-69-8 | 1mg | $1083 | 2026-06-04 | Buy |
| ChemScene | CS-0030900 | Reslizumab 99.4% | 241473-69-8 | 2mg | $1950 | 2026-06-04 | Buy |
| ChemScene | CS-0030900 | Reslizumab 99.4% | 241473-69-8 | 1mg | $1083 | 2026-06-04 | Buy |
| ChemScene | CS-0030900 | Reslizumab 99.4% | 241473-69-8 | 2mg | $1950 | 2026-06-04 | Buy |
| aablocks | AA01UNJ9 | Reslizumab | 241473-69-8 | 1mg | $550 | 2026-05-31 | Buy |
reslizumab Chemical Properties,Uses,Production
Uses
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].
Clinical Use
Treatment of severe eosinophilic asthma
in vivo
Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice[3].
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3].
| Animal Model: | Male B6D2F1/J mice weighing 2025 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3] |
| Dosage: | 010 mg/kg |
| Administration: | Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.) |
| Result: | Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463). |
Drug interactions
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid.
IC 50
IL-5: 91.1 pM (IC50)
Metabolism
Reslizumab is believed to be degraded by enzymatic proteolysis into small peptides and amino acids. As reslizumab binds to a soluble target, linear non-targetmediated clearance is expected.
References
[1] Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. DOI:10.4168/aair.2019.11.2.291
[2] Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. DOI:10.1111/all.14035
[3] Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90. DOI:10.1055/s-0031-1300502
reslizumab Preparation Products And Raw materials
Raw materials
Preparation Products
reslizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 89686 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 | liming@bio-fount.com | China | 9729 | 58 |
| BOC Sciences | -- | info@bocsci.com | USA | 0 | 65 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| Wuhan Topule | +86-02787215551 19945035818 | 2936752263@qq.com | China | 7984 | 58 |
| cjbscvictory | 13348960310 13348960310 | 3003867561@qq.com | China | 10336 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24955 | 58 |
